Novel SOX17 frameshift mutations in endometrial cancer are functionally distinct from recurrent missense mutations.

Authors

Christopher J. Walker, The Ohio State University
Matthew J. O'Hern, The Ohio State University
Vanida A. Serna, The Ohio State University
Takeshi Kurita, The Ohio State University
Mario A. Miranda, The Ohio State University
Caroline E. Sapp, The Ohio State University
David G. Mutch, Washington University School of Medicine in St. Louis
David E. Cohn, The Ohio State University
Paul J. Goodfellow, The Ohio State University

Journal

Oncotarget

Publication Date

2017

Volume

8

Issue

40

Inclusive Pages

68758-68768

Document Type

Open Access Publication

Rights and Permissions

Walker, C.J., O'Hern, M.J., Serna, V.A., Kurita, T., Miranda, M.A., Sapp, C.E., Mutch, D.G., Cohn, D.E., and Goodfellow, P.J. (2017). Novel SOX17 frameshift mutations in endometrial cancer are functionally distinct from recurrent missense mutations. Oncotarget, 8(40), 68758-68768. Copyright: Walker et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Recommended Citation

Walker, Christopher J.; O'Hern, Matthew J.; Serna, Vanida A.; Kurita, Takeshi; Miranda, Mario A.; Sapp, Caroline E.; Mutch, David G.; Cohn, David E.; and Goodfellow, Paul J., "Novel SOX17 frameshift mutations in endometrial cancer are functionally distinct from recurrent missense mutations.." Oncotarget. 8, 40. 68758-68768. (2017).
https://digitalcommons.wustl.edu/open_access_pubs/6226